(Q38632488)

4 September 2017

title

When sepsis persists: a review of MRSA bacteraemia salvage therapy (English)

1 reference

4 September 2017

0 references

2

George Sakoulas

1 reference

4 September 2017

1

Ravina Kullar

1 reference

4 September 2017

Stan Deresinski

3

1 reference

4 September 2017

Sebastiaan J van Hal

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

12 November 2015

1 reference

Journal of Antimicrobial Chemotherapy

4 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

4 September 2017

volume

71

1 reference

4 September 2017

issue

3

1 reference

4 September 2017

page(s)

576-586

1 reference

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Predictors of mortality in Staphylococcus aureus Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

High-dose daptomycin in documented Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus Endocarditis unresponsive to vancomycin therapy with linezolid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Fosfomycin kinetics after intravenous and oral administration to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Combination of Vancomycin and β-Lactam Therapy for Methicillin-ResistantStaphylococcus aureusBacteremia: A Pilot Multicenter Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

Linezolid therapy for infective endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV368

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV368

1 reference

4 September 2017

1 reference